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A Ab bs st tr ra ac ct t
B Ba ac ck kg gr ro ou un nd d: : The dissection of biological pathways and of the molecular basis of disease
requires devices to analyze simultaneously a staggering number of protein isoforms in a given
cell under given conditions. Such devices face significant challenges, including the identification
of probe molecules specific for each protein isoform, protein immobilization techniques with
micrometer or submicrometer resolution, and the development of a sensing mechanism
capable of very high-density, highly multiplexed detection.
R Re es su ul lt ts s: : We present a novel strategy that offers practical solutions to these challenges,
featuring peptide aptamers as artificial protein detectors arrayed on gold electrodes with
feature sizes one order of magnitude smaller than existing formats. We describe a method to
immobilize specific peptide aptamers on individual electrodes at the micrometer scale,
together with a robust and label-free electronic sensing system. As a proving proof of
principle experiment, we demonstrate the specific recognition of cyclin-dependent protein
kinases in whole-cell lysates using arrays of ten electrodes functionalized with individual
peptide aptamers, with no measurable cross-talk between electrodes. The sensitivity is within
the clinically relevant range and can detect proteins against the high, whole-cell lysate
background.
C Co on nc cl lu us si io on ns s: : The use of peptide aptamers selected in vivo to recognize specific protein
isoforms, the ability to functionalize each microelectrode individually, the electronic nature
and scalability of the label-free detection and the scalability of the array fabrication combine to
yield the potential for highly multiplexed devices with increasingly small detection areas and
higher sensitivities that may ultimately allow the simultaneous monitoring of tens or hundreds
of thousands of protein isoforms.
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A comprehensive understanding of protein pathways in
cellular processes and in disease states, as well as the
identification of novel disease biomarkers, will require the
ability to monitor tens or even hundreds of thousands of
protein species in parallel. This represents a significant
technological challenge that will involve the fabrication of
functional high-density micrometer- or submicrometer-
scale arrays, and much attention has been paid to the
development of suitable techniques to enable such investi-
gations [1-3]. While the problem of highly multiplexed
monitoring is tractable at the level of DNA [4,5], the
problem becomes significantly more complex when seeking
to interrogate proteins, for which several alternatively
spliced variants may be expressed from a single gene, with
each variant then being subject to posttranslational
modifications that regulate its activity and conformation.
Thus, the development of the protein equivalent of the
DNA microarray - the protein array - faces several
challenges. The first of these is the identification of specific,
high-affinity robust probe molecules that can bind each of
the range of conformations that native proteins can adopt.
A second is preserving these conformations for analysis,
which will require the development of label-free sensing
strategies. A third is the fact that strategies must be suitable
for the detection of low-abundance proteins in complex
biological solutions. Finally, the fabrication of such arrays
will require a technology capable of immobilizing specific
probe molecules with micrometer or submicrometer
accuracy, as the total surface area required to present very
large numbers of probes will dictate the minimum sample
volume that can be investigated.
Currently, most protein microarrays are produced by dot
printing and consist of surface-immobilized antibodies;
interactions with sample ligands are detected optically [6].
However, the antibodies used are generally made against
denatured, prokaryotically expressed proteins either by
immunization of animals or selection in vitro from phage
display libraries. Consequently, the antibodies predomi-
nantly recognize linear epitopes, which severely hinders
their usefulness in applications to detect native proteins in
complex biological mixtures. Antibodies are also relatively
fragile molecules. Furthermore, when immobilized on a
surface they often exhibit affinities for a number of different
ligands, and hence lack specificity [7]. Alternative probe
molecules, for example DNA and RNA aptamers [8-11],
have been used in protein arrays, and although likely to be
more robust than antibodies, they are also traditionally
selected for binding to prokaryotically expressed proteins
that may not be correctly folded, and will not be correctly
posttranslationally modified. Another problem with current
methodologies is that, although several label-free detection
strategies have been discussed, including surface-plasmon
resonance [12], mass spectroscopy [13], and atomic force
microscopy-based techniques [14,15], the predominant
method for the detection of probe-target interactions is
based on fluorescent labeling of the target proteins. The
fluorescent dyes are typically hydrophobic and may lead to
conformational changes when covalently bound to a
protein that will mask biologically relevant conformations
[6]. Finally, the dot-printing techniques applied to conven-
tional protein arrays offer resolutions of around 0.1 mm.
Although the resolution of these printing and sensing
techniques has improved in recent years, the feature sizes
required for high-density protein arrays capable of handling
extremely small sample volumes are beyond the scope of
such systems. Alternative techniques, which enable the
immobilization of probe molecules on surfaces such as
metal electrodes with resolutions in the micro- or nano-
meter range, are required.
Here we offer solutions to each of these problems. First, we
use robust, in vivo selected peptide aptamers as probe
molecules to replace antibodies. Second, we use a novel
molecular resist technology to functionalize different closely
spaced gold electrodes with different peptide aptamers,
resulting in feature sizes more than one order of magnitude
smaller than current protein-array technologies. This
functionalization technique is inherently scalable to
submicrometer and nanometer feature sizes [16]. Third, we
use an electronic, label-free method to detect binding events
occurring between target proteins in solution and peptide
aptamers immobilized on high-density electrode arrays. The
array devices are fabricated using conventional silicon micro-
fabrication technology, where miniaturization is well
established. This, coupled with the scalability of the electrode
functionalization technique, yields the potential for sub-
micrometer, high-density functional devices with integrated
readout technology capable of performing the many simul-
taneous measurements required for proteome-wide studies.
R Re es su ul lt ts s   a an nd d   d di is sc cu us ss si io on n
P Pe ep pt ti id de e   a ap pt ta am me er r   d de es si ig gn n
Peptide aptamers are short peptide sequences presented and
conformationally constrained in a robust, inert protein
scaffold. They are selected in vivo from large libraries (as
many as 109 unique peptide sequences), yielding binders
with high and very specific affinities for selected targets
[17,18]. The three-dimensional conformational constraint
of the inserted peptide applied by the protein scaffold
greatly increases the affinity of the aptamer for the target
over that of an unconstrained peptide sequence [17-20].
They are distinguished from similar protein or peptide-
based strategies by being selected in eukaryotic cells for
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hybrid approach [21,22]. This maximizes the likelihood
that the target protein is folded in the same way, and
undergoes the same posttranslational modifications, as in
its native environment, providing reliability and confidence
in the specificity of detection.
Traditionally, the Escherichia coli protein thioredoxin A
(TrxA) has been used as a scaffold to present peptide
aptamers [17]. However, many TrxA-based peptide aptamers
are not expressed stably, which limits their use. In addition,
the expression of TrxA in mammalian cells can lead to
detectable phenotypes [23,24], indicating that the bacterial
protein scaffold is able to interact with mammalian
proteins, which would inevitably increase the background
signal in any microarray format. We recently developed a
new biologically inert protein scaffold (Stefin A triple
mutant (STM)) that can present a wide range of different
peptide sequences and has a simplicity and robustness that
allows the production technique to be generic for all targets
[25]. Here, we use peptide aptamers in STM to demonstrate
label-free electronic transduction of biorecognition events
occurring between human cyclin-dependent protein kinases
(CDKs) as target proteins in solution and specific peptide
aptamers immobilized on gold electrode arrays. Immobi-
lization of the STM scaffold is achieved by the introduction
of a single cysteine residue at the amino terminus, enabling
attachment to gold electrodes via S-Au bonds (see [26] for
further details). This cysteine residue is the only cysteine
present in the scaffold and, in three dimensions, is located
at the opposite side to the peptide insert (Figure 1a), thus
separating the peptide insert from the surface.
In this study, we used two different peptide aptamers
displayed by cysteine-modified STM, STMpep2 and STMpep9,
where the subscripts refer to two different peptide inserts
that both recognize cyclin-dependent kinase 2 (CDK2), but
where only STMpep9 binds to cyclin-dependent kinase 4
(CDK4). Both CDK2 and CDK4 belong to a group of
proteins involved in the regulation of the cell cycle; they are
functionally related, yet have less than 46% sequence
identity. STMpep2 and STMpep9 were generated by insertion
of oligonucleotides encoding the CDK-interacting peptide
sequences derived from the thioredoxin-based peptide
aptamers of Colas et al. [17] into restriction sites in the
open reading frame encoding the STM protein scaffold
[25,27]. The binding of CDK2 and CDK4 to the peptide
aptamers was confirmed in vivo using yeast two-hybrid
interaction analysis ([25] and PKF, SJ, DE, SL, AGD and
CW, unpublished work) and in vitro by fluorescence
resonant energy transfer spectroscopy (FRET, Figure 1b) and
dual polarization interferometry (DPI) [27]. The latter
experiments showed that the affinity between surface-
immobilized STMpep9 and CDK2 in a complex biological
mixture compares well to typical values of KD for surface-
immobilized antibodies [27]. These in vitro techniques also
confirmed that the performance of the peptide aptamers is
not affected by tethering the STM scaffold to a surface.
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Peptide aptamer - CDK interactions. ( (a a) ) Schematic diagram of STMpep9-CDK2 complex immobilized on a gold surface via conjugation between the
SH group in a cysteine residue and the gold. ( (b b) ) FRET analysis of STMpep2, STMpep9 and STM in solution on exposure to CDK2, CDK4 and CDK-free
lysate. The peptide aptamers and lysate proteins were tagged with Alexa Fluor 488 and Alexa Fluor 555 fluorescent probes, respectively. The sample
was excited at 488 nm and the resulting fluorescence from the Alexa Fluor 555 dye at 582 nm was measured. Yellow, strong interaction; dark
yellow, medium interaction; black, no detectable interaction.
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Electronic, label-free, on-chip detection of the peptide
aptamer-target interactions is based on monitoring local
changes in the impedance of the electrochemical double
layer, which forms above the surface of a metal electrode
when it is submerged in an electrolyte [28]. Any pertur-
bation of this double layer, for instance by attachment of
proteins to the electrode, alters the electrical properties of
the layer. For example, the complex electrical impedance
Z(ω) is a measure of the extent to which the charge transfer
to and from the electrode is impeded by the surface-
immobilized proteins. Hence, Z(ω) depends on the density,
thickness and internal structure of the protein layer, and any
alteration in this layer, such as the binding of a molecular
target, potentially results in a measurable change of Z(ω)
[29].  Z(ω) can be determined from the response of the
system, i.e. the electrochemical current I, upon applying an
ac electrochemical potential φ of frequency ω to the
electrode. Changes in Z(ω) manifest themselves in changes
of the absolute impedance |Z(ω)| and its phase ϕ(ω), that
is, the phase difference between φ and I. We note that while
|Z(ω)| scales with the electrode surface area, ϕ(ω)  is
independent of the electrode area, and changes in ϕ(ω),
∆ϕ(ω), therefore provide a reliable and reproducible
measure of changes at the electrode surface, which will not
be affected by variability in electrode surface area.
We used electrochemical impedance spectroscopy (EIS) to
determine |Z(ω)| and ϕ(ω) as a function of frequency, ω.
The measurements were performed in the presence of a
redox probe (K3Fe(CN)6
4–/3–) [29]. Gold electrodes
functionalized with STMpep9 or STM were exposed to 45 µl
of a solution containing about 200 ng/µl of purified, recom-
binant CDK2 (rCDK2) expressed in E. coli and subsequently
rinsed with deionized water to remove any excess rCDK2.
Figure 2a,b show ϕ(ω) for STMpep9- and STM-functionalized
electrodes, respectively, both before and after exposure to
purified rCDK2. A shift in ϕ is observed upon rCDK2 bind-
ing to STMpep9, whereas no change was detected in the case
of STM. This shift is more obvious when plotting the differ-
ence in the phase, ∆ϕ, before and after exposure to rCDK2
(Figure 2c). Whereas a pronounced peak in ∆ϕ is measured
for STMpep9, no change in ∆ϕ is observed for STM. These
results demonstrate that ∆ϕ provides a method to detect
binding of the targets to the probe molecules immobilized
on a gold electrode.
To determine the concentration dependence of the phase
shift,  ∆ϕ(c), gold electrodes were functionalized with
STMpep9 and were exposed to 50 µl of phosphate buffer
containing a range of concentrations of purified baculoviral
CDK2 between 25 pM and 100 nM. The electrodes were
subsequently rinsed in phosphate buffer to remove any
excess CDK2 before ϕ(ω) was measured. The results are
shown in Figure 2d from which a sensitivity limit of around
50 pM (approximately equal to 1.5 ng/ml CDK2) can be
determined, which is in the clinically relevant range [7]. The
phase shift is linear on a logarithmic concentration scale
over more than three orders of magnitude. The solid line in
Figure 2d represents a linear fit to the data.
D De et te ec ct ti io on n   o of f   p pr ro ot te ei in ns s   i in n   c co om mp pl le ex x   b bi io ol lo og gi ic ca al l   m mi ix xt tu ur re es s
In biologically and medically relevant samples, the proteins
of interest are typically only present at low concentration
and in complex mixtures of similar biological molecules. To
assess the suitability of our sensing technique for the
detection of proteins in such samples, we prepared gold
electrodes functionalized with STMpep9 and STM, and
exposed them to 35 µl of a whole-cell lysate of CDK2-
expressing yeast cells. Following exposure to yeast lysate, the
devices were thoroughly washed to remove any non-
specifically bound material.
The phase ϕ(ω) of the complex impedance measured for the
different devices is shown in Figure 3. Whereas a distinct
shift in ϕ(ω) is observed between 1 and 103 Hz for STMpep9
exposed to CDK2 lysate (Figure 3a,c), there is no change in
ϕ(ω) across the whole frequency range investigated for STM
exposed to the different aliquots of the same lysate
(Figure 3c). Given that STMpep9 and STM differ only in the
presence (or absence) of the peptide aptamer insert, the
dramatic difference in impedance characteristics following
exposure to the lysate must be related to an interaction with
STMpep9 through the peptide insert. To confirm that this
response is related to the formation of the CDK2-STMpep9
complex, rather than to binding with other species in the
lysate, we exposed a series of STMpep9 functionalized
electrodes to lysate of yeast cells that were not expressing
CDK2 (Figure 3b). The lack of a shift in phase following
exposure to this CDK-free yeast lysate (see Figure 3c)
confirms the specific affinity of STMpep9 for CDK2. The
protein complexity of a yeast lysate (comprising proteins
expressed from approximately 4,000 open reading frames at
any given time) compares favorably with that of medically
relevant biofluids, such as urine (1,400 individual proteins
[30]), and serum or plasma (with estimates of 1,175 [31] to
3,700 [32] individual proteins). These results demonstrate
the ability of our peptide aptamer sensor to unambiguously
detect target-aptamer binding from such samples.
M Mu ul lt ti ip pl le ex xe ed d   d de et te ec ct ti io on n   o of f   p pr ro ot te ei in ns s   u us si in ng g   h hi ig gh h- -d de en ns si it ty y
m mi ic cr ro oa ar rr ra ay ys s
Many future applications in biology (such as systems
analysis of protein interactions) and medicine (such as
personalized medicine protocols) will rely on the ability to
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often the available sample volume is likely to be limited,
particularly in the case of biopsies from patients. Therefore,
high-density arrayed systems - that is, arrays with very small
and very closely packed sensors - are required. Conventional
technologies for generating protein arrays are generally
based on dot-printing strategies with resolutions of the
order of 0.1 mm or more. High-density arrays, with sub-
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F Fi ig gu ur re e   2 2
Electrochemical impedance spectroscopy of the interaction of STMpep9 with recombinant CDK2. ( (a a) ) EIS ϕ(ω) data for a gold surface functionalized
with STMpep9 (orange circles) and subsequently exposed to recombinant CDK2 (blue circles). ( (b b) ) As (a) but following exposure of STM to rCDK2.
( (c c) ) Phase shift (∆ϕ(ω)) of STMpep9 and an STM layer on two independent gold electrodes following exposure to rCDK2. ( (d d) ) Concentration
dependence of the phase shift at 70 Hz. The solid line is a linear fit to the data (see text) provided as a guide to the eye.
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80micrometer or even micrometer feature sizes, are beyond
the scope of these approaches. To enable the immobiliza-
tion of different peptide aptamers on different electrodes
spaced only a few micrometers apart, we developed a
process inspired by our previous work [16]. This enables the
selective functionalization of individual microelectrodes of
an array with resolutions at least an order of magnitude
better than that achieved by conventional techniques.
Selective functionalization of the microelectrodes with
different peptide aptamers was achieved through the
molecular masking process illustrated in Figure 4. The
microelectrode arrays comprised ten individually addres-
sable gold microelectrodes of 20 µm width and separated
by 15 µm, which were first coated with a methyl-terminated
poly(ethylene-glycol)6-thiol (mPEG, Polypure, Oslo,
Norway) layer that prevents nonspecific binding of proteins
during microelectrode functionalization. The thiol-modifi-
cation of the mPEG not only allows the spontaneous
formation of a molecular monolayer on the gold micro-
electrodes through the Au-S bond, but also provides a
means for removing the masking layer from any individual
microelectrode through reductive cleavage of this bond
[33,34]. The quality of the resulting mPEG layers was
verified using water contact-angle measurements and X-ray
photoelectron spectroscopy, and the effectiveness of protein
inhibition was confirmed by fluorescence spectroscopy
(data not shown). After formation of the mPEG layer, the
arrays were soaked for 1 hour in deionized water to remove
residual ethanol and to form a water layer around the
mPEG, which is believed to be crucial in the inhibition of
protein binding [35].
The mPEG molecular mask was selectively removed from an
individual microelectrode by applying an electrochemical
potential of -1.4 V versus Ag/AgCl for 120 seconds using a
potentiostat and identical buffer conditions to those used in
EIS measurements (Figure 4b). Owing to the small spacing
between the microelectrodes, the electric fields generated
during desorption may conceivably influence the
electrochemical potential of neighboring microelectrodes,
potentially disturbing the blocking layer. To prevent this
while allowing scalability to smaller microelectrode
geometries, a second potentiostat was used to hold the
potential of the neighboring microelectrodes at -0.2 V
versus Ag/AgCl during the desorption process. The efficacy
of desorption is monitored by cyclic voltammetry
(Figure 5a). Having desorbed the mPEG molecular mask,
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Electrochemical impedance spectroscopy of the interaction of STMpep9 with CDK2-expressing cell lysate. ( (a a) ) EIS ϕ(ω) data for a gold surface
functionalized with STMpep9 (orange circles) and following exposure to CDK2-expressing yeast lysate (blue circles). ( (b b) ) As (a) but following exposure
of STMpep9 to a CDK-free yeast lysate. ( (c c) ) Data from (a) and (b) plotted as the phase shift (∆ϕ(ω)) for independent electrodes functionalized with
STMpep9 and exposed to either a CDK2-expressing yeast lysate (blue line) or a CDK2-free lysate (orange line). The black line represents the ∆ϕ(ω)
of an STM-functionalized gold electrode following exposure to CDK2-expressing yeast lysate. A phase shift is only detectable upon exposure of
STMpep9 to CDK2, indicating that yeast proteins neither interact nonspecifically with the peptide aptamers nor specifically or nonspecifically with the
electrode surface.
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F Fi ig gu ur re e   4 4
Schematic diagram showing the use of a molecular mask for selective functionalization of a microelectrode array. ( (a a) ) All microelectrodes are initially
protected from functionalization by a protein-inhibiting mPEG monolayer. ( (b b) ) This molecular mask can be released by electrochemical means. The
left microelectrode is addressed, while all neighboring microelectrodes are actively prevented from electrochemical desorption via a second
potentiostat. ( (c c) ) The bare gold microelectrode surface is functionalized with the required peptide aptamer. ( (d d) ) By repeating this cycle it is possible to
independently functionalize multiple microelectrodes with different proteins within a single device. ( (e e) ) The formation of a protein-protein complex
following exposure to a complex biological solution results in a measurable change (phase shift) in ϕ(ω) (central microelectrode). ϕ(ω) remains
constant for all microelectrodes in which target-specific binding does not occur (left and right microelectrodes), thus enabling unambiguous
identification of protein targets within the biological sample.
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(d)the bare gold microelectrode can be functionalized with the
desired protein by incubating the device in 35 µl protein
solution overnight in a sealed humid environment
(Figure 4c). The adsorption of the protein, and the effective-
ness of the mPEG monolayers for masking deposition on
protected microelectrodes, is confirmed using cyclic voltam-
metry and EIS. This process can be repeated to functionalize
further microelectrodes with different proteins (Figure 4d).
Both STMpep9 and STMpep2 show an affinity for CDK2,
whereas only STMpep9 showed an affinity for CDK4
(Figure 1b). We exploit this difference in functionality to
demonstrate our multielectrode array sensor’s ability to
discriminate between binding events occurring on
differently functionalized microelectrodes, fabricated on a
single device. Two separate, nominally identical array
devices with adjacent individual microelectrodes functiona-
lized with the two different peptide aptamers, STMpep9 and
STMpep2, were challenged with either CDK2- or CDK4-
expressing lysate. The EIS results are shown in Figure 5b,c.
Shifts in ϕ(ω) are observed for both the STMpep9- and
STMpep2-functionalized microelectrodes following exposure
to the CDK2-expressing yeast lysate, as expected from the
FRET data (Figure 1b). Conversely, on exposure to CDK4-
expressing yeast lysate, a shift in ϕ(ω) of similar magnitude
was only observed for the STMpep9 functionalized micro-
electrode. The lack of response following exposure of
STMpep2-functionalized microelectrodes to CDK4 indicates
the high selectivity of the functionalization process. In all
cases, ϕ(ω) remains constant for those microelectrodes coated
with mPEG, confirming the efficacy of the inhibiting layer.
C Co on nc cl lu us si io on ns s
In conclusion, we have demonstrated an electronic, label-
free, array-format detection scheme for targeted proteins at
clinically relevant concentrations from complex biological
mixtures. It is based on in-vivo-selected peptide aptamers as
probe molecules and a method for the individual
functionalization of closely spaced electrodes with different
peptide aptamers. Arrays with micrometer-scale dimensions
have been implemented using these techniques. The
electronic detection, fabrication and functionalization
methods are inherently scalable, enabling the generation of
very high-density microelectrode arrays. Such arrays may
ultimately offer the possibility of protein chips providing
massively parallel, label-free analysis of protein-protein
interactions, and may eventually permit the analysis of
multiple protein interactions simultaneously at the level of
a single cell.
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F Fi ig gu ur re e   5 5
Multiplexed detection of proteins in cell lysate using high-density microarrays. ( (a a) ) Cyclic voltammogram of an individual microelectrode protected
with an mPEG protein-inhibiting layer (black line), and following electrochemical desorption of the mPEG monolayer (blue line), and after
functionalization with peptide aptamer STMpep2 (orange line). ( (b b) ) ∆ϕ(ω) of the complex impedance for microelectrodes functionalized with mPEG
(black circles), STMpep2 (orange circles) and STMpep9 (blue circles) following exposure to a lysate containing CDK2. ( (c c) ) As (b) but following exposure
to cell lysate containing CDK4.
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Unless otherwise stated, all chemicals were sourced from
Sigma, Gillingham, UK.
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The peptide aptamers were generated and immobilized on
gold electrodes as described in [26,27]. The yeast lysate was
prepared as detailed in [18,27]. Purified activated baculo-
viral CDK2 was sourced from Cell Signaling Technology
(Danvers, MA).
F FR RE ET T   e ex xp pe er ri im me en nt ts s
STM and STMpep9 were labeled with Alexafluor 488 TFP
ester (Molecular Probes, Invitrogen, Carlsbad, CA). Ten
microliters of protein (approximately 2 mg/ml) were diluted
with 10 µl 1 M NaCO3 aqueous solution, after which 5 µl
Alexafluor dissolved in dimethyl sulfoxide (DMSO) was
added. This mixture was left to incubate for 1 h, after which
1 µl Tris HCl was added to bind unbound dye. The solution
was then filtered through a protein-desalting column
(Pierce, Rockville, IL) to remove excess fluorophores. The
CDK lysates were also dyed in the same way but using
Alexafluor 555 NHS ester (Molecular Probes).
M Mi ic cr ro oe el le ec ct tr ro od de e   a ar rr ra ay y   f fa ab br ri ic ca at ti io on n
Each electrode array structure comprises two opposing
rows of five individually addressable electrodes, each
20 µm wide and separated by 15 µm. The electrode
structure was fabricated using double lift-off
photolithography as follows. N-doped silicon (100)
substrates 30 µm thick with a thermally grown 500 nm
oxide (Compart Technology, Peterborough, UK) were
cleaned in piranha solution (70% H2SO4:30% H2O2) at
100°C for 5 min. The wafer was baked at 150°C for
60 min before polymethyl methacrylate (PMMA, MW
950 kDa, 4% in anisole) was spun on at 1,500 rpm for
40 sec. Following a 90-min bake step at 150°C, Shipley
1805 photoresist was spun onto the PMMA at 5,000 rpm
for 40 sec and baked on a hotplate at 115°C. The wafer was
then cleaved, and individual sections were exposed under
8 mW/cm2 ultraviolet light (UV) in a mask aligner for 4 sec
and developed in MF319 photoresist developer for 60 sec.
The chip was rinsed in deionized water (Millipore,
18.2 Ωcm) and transferred to a UV ozone cleaner where it
was exposed to deep UV for 16 min to expose the PMMA
and harden the upper photoresist layer. Following this
treatment, the PMMA was developed in 3:1 isopro-
panol:methyl isobutyl ketone for 20 sec and rinsed in
isopropanol before the exposed surface was cleaned in 1:5
HCl:H2O. Finally, 15 nm Cr and 50 nm Au were
evaporated onto the wafers, and lifted off using acetone for
30 min. Individual devices were then scribed out, and the
wafer cleaved. The devices were mounted in ceramic
packages with Araldite, wire bonded and cleaned in piranha
solution before functionalization.
E El le ec ct tr ro od de e   f fu un nc ct ti io on na al li iz za at ti io on n
Gold electrodes were functionalized with peptide aptamers
by exposure to 35 µl of either STMpep2, STMpep9 or STM in a
PBS buffer (pH 7.3) for 18 h at room temperature. The
devices were subsequently exposed to the solution con-
taining the target proteins and then rinsed with deionized
water (18.2 Ωcm, Millipore) to remove any excess target
solution. Coating the gold electrodes with mPEG was
achieved by immersing the devices in a 10 mM ethanolic
solution for 96 h.
E El le ec ct tr ro oc ch he em mi ic ca al l   i im mp pe ed da an nc ce e   s sp pe ec ct tr ro os sc co op py y   ( (E EI IS S) )
EIS measurements on individual gold electrodes, where
|Z(ω)| and ϕ(ω) are determined as a function of frequency
between 0.1 Hz and 500 kHz, were carried out using a
custom built three-electrode electrochemical cell with an
electrolyte volume of 50 ml, and a Princeton Applied
Research VSP bipotentiostat/impedance spectrometer in a
common-electrode-to-ground configuration. The gold elec-
trode was used as the working electrode, and a 50-mm-long
high-purity Pt wire (Agar Scientific, Stanstead, UK) was fully
immersed in the electrolyte and used as the common
electrode. The reference electrode was a Ag/AgCl double-
junction ceramic wick electrode (VWR, Lutterworth, UK).
The electrolyte consisted of 100 mM phosphate buffer pH
7.0 containing 10 mM K3Fe(CN)6
4–/3– redox probe which
decreases the impedance of the system by increasing the
measurable quantities and hence improves the sensitivity of
the system [29]. All electrochemical potentials are reported
against a Ag/AgCl reference electrode. Errors in the accuracy
of the phase-shift measurements can be determined from
the cumulative error of the response to CDK-free phosphate
buffer and the measurement error revealed through
repeating the readings; the overall error in the phase shift is
estimated to be ±0.5°.
C Co on nc ce en nt tr ra at ti io on n   d de ep pe en nd de en nc ce e   a an nd d   s se en ns si it ti iv vi it ty y   l li im mi it t
m me ea as su ur re em me en nt ts s
Concentration dependence and sensitivity limits were
measured by exposing the gold electrodes, functionalized
with STMpep9, to phosphate buffer solutions containing
various concentrations of commercial purified activated
CDK2 (Cell Signaling Technology). The STMpep9-functiona-
lized electrodes were placed in 100 mM phosphate buffer
containing 10 mM redox probe (K3Fe(CN)6
4–/3–), and the
impedance measurements were taken repeatedly to confirm
stability. The redox buffer was then removed, and the chip
rinsed in phosphate buffer without redox probe, and
incubated in pure phosphate buffer for 60 min, after which
impedance measurements were repeated to confirm the
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exposed for 1 h to 50 µl phosphate buffer containing the
required concentration of CDK. Final impedance measure-
ments were taken after the gold electrodes were rinsed in
phosphate buffer, transferred to the measurement buffer
(phosphate buffer containing the redox probe), and the
system allowed to equilibrate. All buffers were filtered
through a 0.22 µm filter before use. Each measurement was
repeated three times to confirm the reading, and repeated
sets of measurements were made at 30-min intervals to
ensure stability. The accuracy in the concentration of the
CDK solutions was determined by the accuracy of the
pipettes used and the repeated dilution steps from an initial
100 ng/µl solution. Errors in the accuracy of the phase-shift
measurements were calculated as above and the corres-
ponding error bars are indicated on Figure 2d.
C Cy yc cl li ic c   v vo ol lt ta am mm me et tr ry y   ( (C CV V) )   e ex xp pe er ri im me en nt ts s
The efficacy of the desorption of the molecular masking
layer and the subsequent adsorption of the proteins was
monitored using cyclic voltammetry (CV). These experi-
ments were carried out in the same buffer conditions as the
EIS measurements (100 mM phosphate buffer pH 7.7 with
10 mM K3Fe(CN)6
4–/3– redox probe) and at scan rates of
62 mV/s. The CV curve of the mPEG-coated gold electrode
is shown in Figure 5a. Upon desorption of this layer, the
peak separation on the voltammogram decreases from
425 mV to 100 mV, typical of a gold surface with this redox
probe [29]. Following the adsorption of cysteine-modified
STMpep2 onto the exposed gold electrode, the peaks in the
CV curve decrease and the peak separation increases,
indicating the successful binding of the peptide aptamer to
the surface.
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